Edition:
United States

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

24.18CHF
11:31am EDT
Change (% chg)

CHF0.04 (+0.17%)
Prev Close
CHF24.14
Open
CHF24.04
Day's High
CHF24.28
Day's Low
CHF24.00
Volume
124,220
Avg. Vol
322,867
52-wk High
CHF30.70
52-wk Low
CHF17.10

Chart for

About

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including... (more)

Overall

Beta: --
Market Cap(Mil.): CHF3,163.36
Shares Outstanding(Mil.): 131.04
Dividend: --
Yield (%): --

Financials

  IDIA.S Industry Sector
P/E (TTM): -- 107.68 32.65
EPS (TTM): -1.35 -- --
ROI: -14.77 1.61 12.72
ROE: -24.16 0.32 14.84

BRIEF-Idorsia H1 US GAAP Net Loss At CHF 159 Mln

* US GAAP OPERATING RESULTS IN HY 2018: LOSS OF CHF 155 MILLION

Jul 24 2018

UPDATE 1-Idorsia CEO accelerates fundraising with 505 mln Sfr deal

ZURICH, July 11 Swiss drugmaker Idorsia's Chief Executive Jean-Paul Clozel on Wednesday accelerated fundraising for his drug pipeline, reaping around 505 million Swiss francs ($509 million) by selling new shares and convertible bonds.

Jul 11 2018

Idorsia raises 505 mln Sfr from shares, bonds to fund pipeline

ZURICH, July 11 Swiss drugmaker Idorsia's Chief Executive Jean-Paul Clozel on Wednesday accelerated fundraising for his drug pipeline, reaping around 505 million Swiss francs ($509 million) by selling new shares and convertible bonds.

Jul 11 2018

BRIEF-Idorsia Launches Offering Of New Shares And Convertible Bonds

* IDORSIA LAUNCHES THE OFFERING OF NEW SHARES IN COMBINATION WITH THE OFFERING OF CONVERTIBLE BONDS TO FUND THE DEVELOPMENT OF ITS ADVANCING PIPELINE

Jul 10 2018

After split from Actelion, Idorsia CEO plans to raise more cash in 2019

ALLSCHWIL, Switzerland Swiss biotech Idorsia , spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson , will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters.

Jun 18 2018

BRIEF-Idorsia Initiates Phase 3 Registration Program With Nemorexant For Treatment Of Insomnia

* INITIATES A PHASE 3 REGISTRATION PROGRAM WITH NEMOREXANT (ACT-541468) FOR TREATMENT OF INSOMNIA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 11 2018

BRIEF-Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease

* IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 16 2018

BRIEF-Idorsia: US GAAP Oper Loss Of CHF 74 Mln In Q1 2018

* IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2018

Apr 19 2018

Earnings vs. Estimates